Stocks
Amylyx Pharmaceuticals (AMLX) EBITDA margin US GAAP (year values) |
|||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA margin, % | ? | 78.1% | -6 001% | -28 995% | -903.5% | 10.5% | -106.8% | ||
| Changes by years, y/y, % | -6 079pp | -22 994pp | +28 092pp | +914pp | -39.5% | ||||
Amylyx Pharmaceuticals. EBITDA margin, %
Amylyx Pharmaceuticals. EBITDA margin, changes, pp
Amylyx Pharmaceuticals (AMLX) EBITDA margin US GAAP (quarter values) |
||||||||
| 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA margin, % | ? | 18.5% | 2.06% | -137.4% | -5 203% | -9 432% | -106.8% | |
| Changes by years, y/y, % | +15 820pp | +206pp | -135pp | -5 224pp | -9 450pp | |||
| Changes by quarters, q/q, % | -2pp | -16pp | -139pp | -5 066pp | -4 229pp | |||
